Novavax Inc. buy stratec
Summary
This prediction ended on 02.04.18 with a price of €37.88. The BUY prediction by stratec for Novavax Inc. closed nearly unchanged. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novavax Inc. | 6.123% | 6.123% | -47.098% | -97.745% |
| iShares Core DAX® | 1.804% | -0.748% | 13.168% | 16.408% |
| iShares Nasdaq 100 | -0.182% | -3.412% | 39.976% | 43.502% |
| iShares Nikkei 225® | 0.413% | -7.381% | 18.776% | 2.874% |
| iShares S&P 500 | 0.664% | -1.941% | 28.141% | 42.155% |
Comments by stratec for this prediction
In the thread Novavax Inc. diskutieren
NVAX remains a speculative play, but
its long-run outlook looks comparatively, and I stress comparatively, de-risked. As for the immediate question of the NanoFlu catalyst, while its failure would not bury NVAX once and for all, it would drive shares into the ground for the foreseeable future.
In preclinical trials, NVAX’s novel flu vaccine outperformed the market leader Sanofi’s Fluzone HD. While preclinical success may not translate into human trial success, a lot is riding on the NanoFlu data readout. There is no “sure thing” in clinical trial data, especially early-stage trials. If NVAX’s flu vaccine can show efficacy comparable to Fluzone HD, it will immediately garner a whole lot more attention, sending shares up further – and perhaps even attract a takeover bid.
stratec stimmt am 31.01.2018 dem Buy-Crowdsentiment mit dem Kursziel 2.4$ zu.